These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 1488870)

  • 41. Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders.
    Ferrero D; Tarella C; Pregno P; Pileri A; Gallo E
    Cancer Res; 1986 Feb; 46(2):975-80. PubMed ID: 3455679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MPN blast phase: clinical challenge and assessing response.
    Mesa RA; Tibes R
    Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
    [No Abstract]   [Full Text] [Related]  

  • 43. [Chronic myeloproliferative disorders. The new WHO classification].
    Thiele J; Kvasnicka HM
    Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The histopathology of chronic myeloproliferative diseases.
    Georgii A; Buesche G; Kreft A
    Baillieres Clin Haematol; 1998 Dec; 11(4):721-49. PubMed ID: 10640214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Myeloproliferative neoplasms: new translational therapies.
    Mascarenhas J; Hoffman R
    Mt Sinai J Med; 2010; 77(6):667-83. PubMed ID: 21105128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders.
    Peschel C; Aulitzky WE; Huber C
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():129-34. PubMed ID: 8951783
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A
    Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy.
    Franco V; Florena AM; Aragona F; Campesi G
    Pathol Res Pract; 1993 Feb; 189(1):52-7. PubMed ID: 8516217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms.
    Tadmor T; Bejar J; Attias D; Mischenko E; Sabo E; Neufeld G; Vadasz Z
    Am J Hematol; 2013 May; 88(5):355-8. PubMed ID: 23494965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
    Stein BL; Tiu RV
    J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloproliferative syndromes: diagnosis and therapeutic options.
    Hellmann A
    Pol Arch Med Wewn; 2008 Dec; 118(12):756-60. PubMed ID: 19202955
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Diagnosis and therapy of chronic myeloproliferative disorders].
    Kimura A
    Nihon Naika Gakkai Zasshi; 1998 Mar; 87(3):507-12. PubMed ID: 9577584
    [No Abstract]   [Full Text] [Related]  

  • 55. Bone marrow stromal cells in myeloproliferative disorders.
    Hirata J; Takahira H; Kaneko S; Nishimura J; Nawata H
    Acta Haematol; 1989; 82(1):35-9. PubMed ID: 2505472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
    Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
    Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone marrow angiogenesis: methods of quantification and changes evolving in chronic myeloproliferative disorders.
    Kvasnicka HM; Thiele J
    Histol Histopathol; 2004 Oct; 19(4):1245-60. PubMed ID: 15375769
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases].
    Nafe R; Holgado de Colombo S; Choritz H; Georgii A
    Pathologe; 1995 Jan; 16(1):34-40. PubMed ID: 7886012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of interferon therapy on bone marrow morphology in chronic myeloid leukemia: a cytochemical and immunohistochemical study of trephine biopsies.
    Thiele J; Zirbes TK; Kvasnicka HM; Lorenzen J; Niederle N; Leder LD; Fischer R
    J Interferon Cytokine Res; 1996 Mar; 16(3):217-24. PubMed ID: 8697144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.